Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Champions Biotechnology, Pharmaceutical Industries sign Master Service Agreement

Champions Biotechnology, Inc., an oncology drug development company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced that a Master Service Agreement with Teva Pharmaceutical Industries has been commissioned for the testing of a novel anti-angiogenic compound in the Champions Tumorgraft™ platform.

7 Dec 2010

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology provides greater understanding of the optimal use of several BCR-ABL inhibitors for the treatment of acute lymphoblastic leukemia and chronic myeloid leukemia, and how a new gene target functions for several myeloid malignancies.

6 Dec 2010

MRI scans quantifies disruptions in blood brain barrier, identifies TBI patients at risk of developing PTE

Approximately 5 - 30% of patients with traumatic brain injury (TBI) develop post traumatic epilepsy (PTE). The onset of seizures in patients who are susceptible to PTE can range from weeks or months to more than a decade after TBI. In a presentation today at the 64th American Epilepsy Society annual meeting, scientists report that the analysis of routine MRI scans can reliably quantify the disruptions in the blood brain barrier that are increasingly believed to be a prominent contributor to epilepsy development.

6 Dec 2010

Patients with H1N1 flu die due to over-reactive immune response: Research

On November 19, Jason Martin returned to the Medical Intensive Care Unit at Vanderbilt University Medical Center for the first time since he nearly died there during last year's H1N1 flu pandemic. The tall and burly Warren County, TN, ambulance worker - a 30-year-old, father of three young children - broke down and hugged some of the nurses he recognized.

6 Dec 2010

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.

4 Dec 2010

New approach to biomarker detection for early lung cancer diagnosis

Even with astounding advances in genomic science, genetic analysis of disease remains largely a measure of risk rather than actual disease state. A truer and more immediate measure of health can be obtained by analysis of proteins, especially those that are biomarkers of disease state.

2 Dec 2010

Early autism diagnostic test on the horizon

Soon scientists may have a test to diagnose autism spectrum disorders using magnetic resonance imaging (MRI) scans. As of now this dreaded developmental disorder is typically diagnosed through observations, along with educational and psychological testing.

2 Dec 2010

AES annual meeting features special session on implications of combat-induced traumatic brain injury

A panel of medical experts will discuss the implications of combat-induced traumatic brain injury (TBI) today in an opening day session of the 64th American Epilepsy Society (AES) Annual Meeting here at the Henry B. Gonzales Convention Center. The session will focus on post traumatic seizure care from treatment on the battlefield to veteran hospitals and the civilian community.

2 Dec 2010

Biomagnetics identifies second biomarker for tuberculosis assay

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced the identification of a second biomarker for development of a tuberculosis assay.

2 Dec 2010

New cerebrospinal fluid biomarkers to monitor Parkinson's disease

KineMed Inc. presents data on the new use of cerebrospinal fluid biomarkers of microtubule-mediated neuronal transport for the monitoring of disease progression and the advancement of therapeutic interventions in Parkinson's disease, a debilitating neurological condition with considerable unmet need for new treatments.

1 Dec 2010

Metabolon announces publication of diabetes study in PLoS ONE journal

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of "Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting" in PLoS ONE.

1 Dec 2010

USC purchases WaferGen SmartChip system for Molecular Pathways and Drug Discovery center

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced that the University of Southern California (USC) has purchased the WaferGen SmartChip system for its USC Center for Molecular Pathways and Drug Discovery to discover and validate biomarkers for pancreatic and colorectal cancer applications to expedite the development of a cancer therapy. USC purchased a solution that includes the SmartChip platform and validated gene panels for biomarker profiling.

1 Dec 2010

Aushon, LightArray enter strategic partnership to provide multiplex biomarker products and services in China

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services for biomarker discovery, development and analysis announced during the ChinaTrials 2010 Summit in Beijing, China, that it has entered into a partnership with LightArray Biotech Company, Ltd., to provide Aushon's comprehensive suite of multiplex biomarker products and services to pharmaceutical, biotechnical, and academic research institutions located in mainland China.

1 Dec 2010

Neuraltus reports positive results from NP001 Phase 1 study for ALS

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1 clinical study of NP001 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).

30 Nov 2010

Quintiles, London Genetics enter strategic alliance to offer pharmacogenetics solutions for personalized medicine

Quintiles, the world's leading biopharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the biopharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine. Financial terms were not disclosed.

30 Nov 2010

Transgenomic signs definitive agreement to acquire diagnostic business of Clinical Data

Transgenomic, Inc. announced today the signing of a definitive agreement for Transgenomic to acquire the diagnostic business of Clinical Data, Inc. This acquisition includes a suite of proprietary genetic commercial tests, certain proprietary biomarker assays, and the CLIA-certified laboratory operations of Clinical Data for a purchase price of approximately $15.4 million, primarily in cash and notes.

29 Nov 2010

MEDIAN Technologies receives OSEO 'Innovative Company' accreditation

MEDIAN Technologies, the leading provider of clinical applications for quantitative management of treatment responses in oncology imaging, today announced that it had obtained "Innovative Company" accreditation from OSEO (the French state innovation agency). This accreditation enables innovation-focused French investment funds (Fonds Communs de Placement dans l'Innovation) to invest in MEDIAN Technologies and enjoy a number of fiscal advantages.

29 Nov 2010

Almac announces additional dedicated Late Stage Customisation Suite

With a growing requirement to support our clients with their EU product launches, reduce stock holdings and provide greater flexibility with regional packs, Almac has added an additional dedicated Late Stage Customisation Suite to the company's commercial facilities.

25 Nov 2010

Radical change to Alzheimer’s management

The first disease-modifying drugs are expected to launch from 2013, radically changing the way Alzheimer’s disease is treated. With the potential to successfully slow or halt the progression of Alzheimer’s, blockbuster revenues are beckoning for such pipeline drugs, claims independent market analyst, Datamonitor.

23 Nov 2010

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).

23 Nov 2010

Biomarker News and Research

Further Reading

Champions Biotechnology, Pharmaceutical Industries sign Master Service Agreement

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

MRI scans quantifies disruptions in blood brain barrier, identifies TBI patients at risk of developing PTE

Patients with H1N1 flu die due to over-reactive immune response: Research

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

New approach to biomarker detection for early lung cancer diagnosis

Early autism diagnostic test on the horizon

AES annual meeting features special session on implications of combat-induced traumatic brain injury

Biomagnetics identifies second biomarker for tuberculosis assay

New cerebrospinal fluid biomarkers to monitor Parkinson's disease

Metabolon announces publication of diabetes study in PLoS ONE journal

USC purchases WaferGen SmartChip system for Molecular Pathways and Drug Discovery center

Aushon, LightArray enter strategic partnership to provide multiplex biomarker products and services in China

Neuraltus reports positive results from NP001 Phase 1 study for ALS

Quintiles, London Genetics enter strategic alliance to offer pharmacogenetics solutions for personalized medicine

Transgenomic signs definitive agreement to acquire diagnostic business of Clinical Data

MEDIAN Technologies receives OSEO 'Innovative Company' accreditation

Almac announces additional dedicated Late Stage Customisation Suite

Radical change to Alzheimer’s management

Erbitux development program featured in ASCO's Clinical Cancer Advances report for third consecutive year

Breaking Barriers: ANDYSMANCLUB's Fight for Men's Mental Health on World Mental Health Day

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Innovations in baculovirus–insect cell expression systems

Latest Life Science News